Mark Avagliano joins Georgiamune
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano (pictured, above) as chief business officer (CBO).
The news comes as Georgiamune closes out a year in which it has launched three assets into clinical trials.
With Phase II testing ambitions set for 2025 across the three clinical assets in both cancer and autoimmune diseases (GIM-122, GIM-531 and GIM-407), it is hoped that Mr Avagliano’s combination of business acumen and sector expertise will further empower the company to meet these pivotal milestones while ensuring that its robust earlier stage pipeline progresses through development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze